N@N

Sucampo Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference

^{Published on 2008-12-09 10:33:12 - Market Wire}
 

BETHESDA, MD--([ BUSINESS WIRE ])--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that management will participate in a panel discussion titled Going With Your Gut: New Treatments for GI Disorders at the RBC Capital Markets Healthcare Conference in New York on Wednesday, December 10, 2008 at 1:30pm.

The panel discussion will be webcast and may be accessed at the "For Investors" section of the Company's website, [ www.sucampo.com ]. Investors interested in listening to the live audio webcast should log on before the conference call begins in order to download any software required. The archive of the panel discussion will remain available for several days.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and Advisor, International Business Development.

Sucampo Pharmaceuticals is marketing AMITIZA^® (lubiprostone) 24 mcg in the U.S. for Chronic Idiopathic Constipation in adults and AMITIZA 8 mcg in the U.S. to treat Irritable Bowel Syndrome with Constipation in adult women. Sucampo is also developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo Pharmaceuticals has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals has two wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., headquartered in Oxford, UK, with a branch office in Basel, Switzerland, and Sucampo Pharma, Ltd., located in Tokyo and Osaka, Japan. To learn more about Sucampo Pharmaceuticals and its products, visit [ www.sucampo.com ].

AMITIZA^® is a registered trademark of Sucampo Pharmaceuticals, Inc.